Durability
of HBeAg Seroconversion After Adefovir Treatment HBe
seroconversion, or loss of HBe antigen
(HBeAg) and development of anti-HBe antibodies, is a marker for successful
treatment of chronic hepatitis B. A
study presented at the recent Digestive Disease Week 2006 conference in Los Angeles
showed that 91% of patients treated with adefovir
(Hepsera) had durable HBe seroconversion lasting an average of three years This
study enrolled 45 chronic hepatitis B patients with compensated liver disease
who experienced HBe seroconversion and suppression of HBV
DNA to below 100,000 copies/mL during treatment with 10 mg once daily adefovir.
Median duration of adefovir therapy was 54.4 weeks before seroconversion and 37
weeks after seroconversion. After completion of treatment, subjects were followed
for a median of 143 weeks. Results  | 41
patients (91%) maintained durable HBe seroconversion during follow-up (37% followed
for 2-3 years and 46% for more than three years). | | Four
patients (9%) did not maintain seroconversion; seroreversion (becoming HBeAg positive
again) occurred at week 12 for three patients and at week 16 for one patient. | |
At the time of seroreversion, all four patients had HBV DNA greater than 100,000
copies/mL and ALT levels of 84-222 IU/L. | | Durable
HBe seroconversion, or lack thereof, was not associated with patient age, gender,
baseline HBV DNA, or baseline ALT; all four patients who experienced seroreversion
were Asian and had HBV genotype C. | | For
all patients, the median HBV DNA at the last measurement after stopping adefovir
was 3.04 log copies/mL and the median ALT level was 28 IU/mL. | | Median
duration of adefovir therapy before seroconversion was longer among patients
who eventually experienced seroreversion compared with those who maintained seroconversion
(108 vs 48 weeks, respectively). | | Median
duration of adefovir therapy after seroreversion was shorter among patients
who eventually experienced seroreversion compared with those who maintained seroconversion
(22 vs 41 weeks, respectively). |
|
Conclusion The
researchers concluded that HBe seroconversion was durable after adefovir treatment
in 91% of patients over a median follow-up period of three years. 6/09/06 Reference
T
Chang, ML Shiffman, M Tang, and others. Durability of HBeAg seroconversion following
adefovir dipivoxil treatment for chronic hepatitis B (CHB). Abstract T1844. Digestive
Disease Week 2006. May 20-25, 2006. Los Angeles, California. 
Additional
Adefovir Articles Posted on HIV and Hepatitis.com
Adefovir
Rapidly
Suppresses HBV in HBeAg-negative Patients Who Develop Resistance to Lamivudine
-
12/16/05
Efficacy
and Tolerability of Adefovir- versus Tenofovir-based Combination Therapy
Regimens in a Cohort of Individuals with Chronic Hepatitis B -
11/30/05
In
Comparison to Adefovir, the Efficacy of Tenofovir Seems Unchanged by the
Presence of Lamivudine-resistant HBV -
11/23/05
Experimental
HBV Drug Pradefovir: Safety, Tolerability, Antiviral Activity, and Pharmacokinetics
-
11/21/05
Five-year
Treatment with Adefovir Results in Regression of Liver Fibrosis in Patients
with HBeAg-negative Chronic Hepatitis B -
11/16/05
Adefovir
Add-on Therapy after Emergence of Lamivudine Resistance Is Effective and Unlikely
to Result in Resistance to Adefovir in HIV-HBV Coinfected Patients -
11/16/05
A
Cost-Effectiveness Analysis of Treatment Alternatives for Hepatitis B Cirrhosis -
11/16/05
Long-term
Treatment with Adefovir Dipivoxil Is More Cost Effective Than Lamivudine for HBeAg-negative
Patients with Chronic Hepatitis B -
11/16/05
Effective
Treatment Does Not Reach HBV Patients in the Netherlands Due to Lack of Use by
Specialists of Treatment Guidelines -
11/16/05
Adefovir
Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated
Liver Disease and Lamivudine-resistant Hepatitis B Virus - 10/19/05
Resistance
to Adefovir Dipivoxil (Hepsera) Can Be Associated with Significant Virologic
Breakthough and Fatal Hepatic Decompensation
- 5/27/05
Adefovir
Dipivoxil Demonstrates Sustained Efficacy in HBeAg-negative Chronic Hepatitis
B Patients
- 5/23/05
Increasing
Serologic, Virologic and Biochemical Response Over Time to Adefovir Dipivoxil
(ADV) 10 mg in HBeAg+ Chronic Hepatitis B Patients
- 5/23/05
Pegylated
Interferon Alfa-2b (PegIntron) and Adefovir Dipivoxil (Hepsera) Combination
Therapy in Chronic Hepatitis B (CHB) Patients Leads to a Strong Suppression of
cccDNA and High Rates of HBe and HBs Seroconversion
- 5/16/05
Predictors
of a Poor Outcome in Patients Treated with Adefovir for Reactivation of
Chronic Hepatitis B Due to Lamivudine-resistant HBV Mutants
- 5/09/05
|
